In its current release, the Federal Biomedical Agency of Russia revealed the details of the developed antidote for coronavirus. Called "World 19" entiotropic agent as an active component uses small interfering RNAs (miRNAs), which specifically destroy a specific region of the viral genome, which is responsible for its replication.

Experiments on animals have shown that the concentration of the virus is reduced by 10 thousand times, the drug does not affect the human genome and is absolutely safe for humans. In addition, the regions of the virus genome, selected as a target for the drug's action, are highly conservative, practically do not undergo mutations, and therefore remain relevant for any of the known lines of coronavirus, including the British and Indian ones, said the head of the Agency Veronika Skvortsova.

The pronounced antiviral effect of the drug, confirmed in the experiment, made it possible to assume its maximum effectiveness in the earliest period after human infection - in the first 2-3 days, in the so-called viral phase.

Permission for the first phase of clinical trials was received on December 30, 2020. Taking into account that MIR 19 is a new molecule that is first used in humans, the first phase of clinical trials was carried out especially carefully and was completed on March 27, 2021.The first phase demonstrated good tolerability of the drug and its complete safety with single and repeated use in wide dose range.

04/14/2021 official permission was obtained to conduct phase II clinical trials and from 26.04.2021 they began in the clinical centers of the FMBA of Russia in Moscow and the Moscow region, as well as in St. Petersburg and the Leningrad region.

The end of the II phase of clinical trials is planned by mid-August 2021. and in case of confirmation of the effectiveness of the drug in patients with a new coronavirus infection, the drug will be submitted for registration.

As I understand, it is final warning.